MacroGenics, Inc. (MGNX)
4.06
+0.32
(+8.56%)
USD |
NASDAQ |
Sep 28, 16:00
4.06
0.00 (0.00%)
After-Hours: 19:03
MacroGenics Research and Development Expense (TTM) : 134.55M for June 30, 2026
Research and Development Expense (TTM) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Research and Development Expense (TTM) Data
| Date | Value |
|---|---|
| June 30, 2026 | 134.55M |
| March 31, 2026 | 135.36M |
| December 31, 2025 | 140.00M |
| September 30, 2025 | 144.57M |
| June 30, 2025 | 152.36M |
| March 31, 2025 | 163.39M |
| December 31, 2024 | 169.65M |
| September 30, 2024 | 178.27M |
| June 30, 2024 | 167.74M |
| March 31, 2024 | 158.24M |
| December 31, 2023 | 156.94M |
| September 30, 2023 | 153.91M |
| June 30, 2023 | 171.08M |
| March 31, 2023 | 179.52M |
| December 31, 2022 | 195.16M |
| September 30, 2022 | 205.64M |
| June 30, 2022 | 207.32M |
| March 31, 2022 | 214.23M |
| December 31, 2021 | 208.83M |
| September 30, 2021 | 195.34M |
| June 30, 2021 | 190.00M |
| March 31, 2021 | 188.28M |
| December 31, 2020 | 181.24M |
| September 30, 2020 | 191.06M |
| June 30, 2020 | 194.22M |
| Date | Value |
|---|---|
| March 31, 2020 | 191.61M |
| December 31, 2019 | 192.58M |
| September 30, 2019 | 190.28M |
| June 30, 2019 | 191.64M |
| March 31, 2019 | 192.22M |
| December 31, 2018 | 190.83M |
| September 30, 2018 | 182.89M |
| June 30, 2018 | 177.65M |
| March 31, 2018 | 160.10M |
| December 31, 2017 | 147.23M |
| September 30, 2017 | 139.36M |
| June 30, 2017 | 128.67M |
| March 31, 2017 | 127.55M |
| December 31, 2016 | 122.09M |
| September 30, 2016 | 121.03M |
| June 30, 2016 | 114.83M |
| March 31, 2016 | 104.15M |
| December 31, 2015 | 98.27M |
| September 30, 2015 | 87.88M |
| June 30, 2015 | 82.41M |
| March 31, 2015 | 77.08M |
| December 31, 2014 | 69.79M |
| September 30, 2014 | 64.13M |
| June 30, 2014 | 56.27M |
| March 31, 2014 | 49.98M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (TTM) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Research and Development Expense (TTM) Benchmarks
| Gilead Sciences, Inc. | 5.943B |
| Xencor, Inc. | 255.76M |
| ACADIA Pharmaceuticals, Inc. | 331.01M |
| Alnylam Pharmaceuticals, Inc. | 1.509B |
| Anika Therapeutics, Inc. | 27.45M |